Evropská unie - maltština - EMA (European Medicines Agency)

chanelle pharmaceuticals manufacturing limited - sevoflurane - anestetiċi ġenerali, - dogs; cats - għall-induzzjoni u l-manutenzjoni ta 'l-anestesija.

Evropská unie - maltština - EMA (European Medicines Agency)

sanofi winthrop industrie - lixisenatide - diabetes mellitus, tip 2 - drugs used in diabetes, glucagon-like peptide-1 (glp-1) analogues - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.

Evropská unie - maltština - EMA (European Medicines Agency)

esteve pharmaceuticals gmbh - ziconotide - injections, spinal; pain - analġeżiċi - ziconotide huwa indikat għall-kura ta 'uġigħ sever u kroniku f'pazjenti li jeħtieġu analġeżija intrateġika (it).

Evropská unie - maltština - EMA (European Medicines Agency)

serono europe limited - efalizumab - psorajiżi - immunosoppressanti - trattament tal-pazjenti adulti ma moderat biex psoriasis plakka kronika severi li jkunu naqqsu milli jwieġbu għal, jew li jkollhom a contraindication li, jew li huma intolerant li t-terapiji sistematiċi oħra inklużi ciclosporin, methotrexate u puva (ara taqsima 5. 1 - effikaċja klinika).

Evropská unie - maltština - EMA (European Medicines Agency)

indivior europe limited - buprenorphine, naloxone - disturbi relatati ma 'opjojdi - drogi oħra tas-sistema nervuża - trattament ta 'sostituzzjoni għal dipendenza fuq opioid-drug, fi ħdan qafas ta' trattament mediku, soċjali u psikoloġiku. l-intenzjoni tal-komponent ta 'naloxone hija li tiskoraġġixxi l-użu ħażin minn ġol-vina. il-kura hija maħsuba għall-użu f'adulti u adolexxenti ta 'aktar minn 15-il sena li qablu li jiġu ttrattati għall-vizzju.

Evropská unie - maltština - EMA (European Medicines Agency)

novo nordisk a/s - liraglutide - diabetes mellitus, tip 2 - drogi użati fid-dijabete - victoza huwa indikat għat-trattament ta ' adulti, l-adoloxxenti u t-tfal bejn l-10 snin u l-fuq li mhumiex ikkontrollati biżżejjed bil-dijabete tat-tip 2 mellitus bħala żieda mad-dieta u l-exerciseas monoterapija b'metformin meta jitqies mhux xieraq minħabba l-intolleranza jew contraindicationsin minbarra l-oħra prodotti mediċinali għall-kura tad-dijabete. għall-riżultati tal-istudju fir-rigward tal-kombinazzjonijiet, l-effetti fuq il-kontroll gliċemiku u episodji kardjovaskulari, u l-popolazzjonijiet studjati.

Evropská unie - maltština - EMA (European Medicines Agency)

merck sharp dohme ltd  - peginterferon alfa-2b - epatite Ċ, kronika - immunostimulanti, - adults (tritherapy)viraferonpeg in combination with ribavirin and boceprevir (tritherapy) is indicated for the treatment of chronic-hepatitis-c (chc) genotype-1 infection in adult patients (18 years of age and older) with compensated liver disease who are previously untreated or who have failed previous therapy. jekk jogħġbok irreferi għall-ribavirin u boceprevir-sommarji tal-karatteristiċi tal-prodott (smpcs) meta viraferonpeg ikun ser jintuża flimkien ma ' dawn il-mediċini. adults (bitherapy and monotherapy)viraferonpeg is indicated for the treatment of adult patients (18 years of age and older) with chc who are positive for hepatitis-c-virus rna (hcv-rna), including patients with compensated cirrhosis and / or co-infected with clinically stable hiv. viraferonpeg f'kombinazzjoni ma ' ribavirin (bitherapy) huwa indikat għall-kura ta chc infezzjoni fil-pazjenti adulti li ma kienux trattati qabel inkluż pazjenti b'hiv klinikament stabbli ko-infezzjoni u f'pazjenti adulti li jkunu fallew it-trattament preċedenti bl-interferon-alpha (pegilata jew mhux pegilata) u terapija kombinata b'ribavirin jew monoterapija b'interferon alfa. il-monoterapija b'interferon, li tinkludi viraferonpeg, tintuża l-aktar f'każ ta 'intolleranza jew ta' kontra-indikazzjoni għal ribavirin. jekk jogħġbok irreferi għall-ribavirin smpc meta viraferonpeg ikun ser jintuża flimkien ma ' ribavirin. paediatric population (bitherapy)viraferonpeg is indicated in a combination regimen with ribavirin for the treatment of children three years of age and older and adolescents, who have chronic hepatitis c, previously untreated, without liver decompensation, and who are positive for hcv-rna. meta tiddeċiedi li ma li tipposponi it-trattament sakemm il-ħajja adulta, huwa importanti li wieħed jikkunsidra li l-terapija kombinata indotta-inibizzjoni tat-tkabbir li jista'jkun irriversibbli f'xi pazjenti. id-deċiżjoni li l-kura għandha tittieħed każ b'każ. jekk jogħġbok irreferi għall-ribavirin smpc għal kapsuli jew soluzzjoni orali meta viraferonpeg ikun ser jintuża flimkien ma ' ribavirin.

Evropská unie - maltština - EMA (European Medicines Agency)

bial - portela & ca, s.a. - eslicarbazepine acetate - epilessija - anti-epilettiċi, - zebinix huwa indikat bħala terapija adjunctive fl-adulti, adolixxenti u tfal b ' età hawn fuq 6 snin, ma b'sekwestru parzjali-iskoppjar bi jew mingħajr ġeneralizzazzjoni sekondarja.

Evropská unie - maltština - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - aġenti għad-dermatite, esklużi kortikosterojdi - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Evropská unie - maltština - EMA (European Medicines Agency)

gedeon richter - idroklorur tal-karprażina - skizofrenija - psikolettiċi - reagila huwa indikat għall-kura ta 'l-iskiżofrenja f'pazjenti adulti.